Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda
pembrolizumab · Merck Sharp & Dohme
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
An alternative 400 mg every six weeks schedule across adult indications approved at the time, alongside the existing 200 mg every three weeks schedule.
LAMPGEN ANALYSIS
Why it matters
Offered a longer interval between infusions for eligible adults while retaining the prior schedule.
What research teams should watch
Update order sets and preserve timely symptom reporting between infusion visits.
PRIMARY RECORDS